Southlake is the second hospital in Ontario and one of the first four hospitals in Canada to use this technology, after receiving 'special access' authorization from Health Canada ...

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive standard dataset of ...

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and m ...